BNTC Benitec Biopharma Inc.
Distress ·
Benitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time.
Benitec Biopharma is issuing 2,043,000 shares and 300,000 pre-funded warrants at $13.00 a share. The prospectus says 900,000 of the shares go directly to Averill funds that are affiliates of Suvretta Capital, while the pricing release names Suvretta Capital itself.
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on novel genetic medicines. Its lead product candidate, BB-301, is an AAV-based gene therapy for oculopharyngeal muscular dystrophy, or OPMD, a chronic, life-threatening genetic disorder. BB-301 is designed to permanently silence the disease-causing gene and simultaneously replace the mutant gene with a functional gene, an approach the company calls silence and replace. The underlying platform, DNA-directed RNA interference, or ddRNAi, combines RNA interference with viral delivery agents typically associated with gene therapy. BB-301 has Orphan Drug Designation and Fast Track Designation in the United States and Orphan Drug Designation in the European Union. The Investigational New Drug application for BB-301 was approved to proceed by the U.S. Food and Drug Administration in June 2023, and the first study subject was treated in the BB-301 Phase 1b/2a clinical trial in November 2023. The company says it will require additional financing to progress its product candidates through future inflection points.
| Product or program | What it is | Stage |
|---|---|---|
| BB-301 | AAV-based silence and replace gene therapy for OPMD-derived dysphagia | Phase 1b/2a clinical trial |
| ddRNAi platform | DNA-directed RNA interference combined with AAV viral vectors |
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Research and development | $23.4 million | $18.3 million |
| Net income (loss) | -$45.5 million | -$37.9 million |
| Cash from operations | -$16.5 million | -$23.6 million |
| Cash and equivalents | $180.0 million | $97.7 million |
Benitec Biopharma Inc. trades under the ticker BNTC on NASDAQ.
Benitec Biopharma Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Benitec Biopharma Inc. is 1808898. Its filings are on SEC EDGAR.
34,882,726 shares as of 2026-09-04, per the cover page of its 10-K filed 2026-09-14.
Our directory records Benitec Biopharma Inc. under United States.
Our directory classifies Benitec Biopharma Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Benitec Biopharma Inc. is US08205P2092.
aibio.space lists Benitec Biopharma Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on novel genetic medicines. Its lead product candidate, BB-301, is an AAV-based gene therapy for oculopharyngeal muscular dystrophy, or OPMD, a chronic, life-threatening genetic disorder.
BB-301: AAV-based silence and replace gene therapy for OPMD-derived dysphagia Stage: Phase 1b/2a clinical trial.
ddRNAi platform: DNA-directed RNA interference combined with AAV viral vectors
Benitec Biopharma Inc. reported a net loss of $45.5 million for the fiscal year ended Jun 30, 2026, and used $16.5 million of cash in operations, per its annual report to the SEC.
$23.4 million in the fiscal year ended Jun 30, 2026, per its annual report.
$180.0 million in cash at Jun 30, 2026, per its 10-K.
Reported a change of independent auditor. SEC Form 8-K (Items 4.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 4.02). Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio